Leerink Partners reiterates Market Perform on BioMarin stock at $62

BioMarin reported LTM revenue growth of 12.87% and analysts project ~18% revenue growth for 2026; shares trade at $60.74 while Leerink reiterated Market Perform with a $62 target. Several firms raised price targets (Barclays and Freedom to $105, Canaccord to $104, Truist $100, Cantor $85) as management highlighted a pending Amicus acquisition, recent Palynziq adolescent approval, and two upcoming Phase 3 readouts (Voxzogo in hypochondroplasia and BMN401 for ENPP1). Analysts and management expressed cautious optimism but flagged competitive pressure on Voxzogo and said more detail on the Amicus deal is expected later this year.

Analysis

The recent update re‑frames BioMarin from a single-product growth story into a multi-asset integration play; the non-obvious lever is cadence risk from marrying two rare-disease portfolios. Integration will drive gross-margin and SG&A dynamics over 6–18 months as overlapping commercial footprints are rationalized and CMO/fill‑finish capacity is reallocated — a successful consolidation can convert near‑term revenue volatility into higher long‑term FCF.

Competitive pressure in achondroplasia (Ascendis and others) is not just a market‑share story but a pricing and channel mix story: more convenient therapies accelerate uptake but also compress ASPs and drive payor arbitrage toward bundle negotiations, shifting revenue from high‑margin specialty clinics to hospital/outpatient channels. That channel shift increases working capital and DSO risk over the next 2–4 quarters and could materially widen net cash burn if launch economics underperform.

Key binary catalysts are the upcoming Phase‑3 readouts and the management update on the acquisition integration; these are 3–12 month windows where volatility will spike and implied options premium should widen. Tail risks include readout failures, regulatory setbacks, and integration execution that could reduce combined asset value by >30% versus current expectations, while successful readouts plus smooth integration could re‑rate the name by 40–80% over 12–24 months depending on price realization and cost synergies.

Key Decisions for Investors

• Event‑driven long (BMRN): Buy a 12–18 month call spread (buy LEAP, sell higher strike) sized at 3–5% of portfolio to capture positive phase‑3 readouts and integration clarity. Target asymmetric payoff: pay ~5% notional for potential 50–100% upside if catalysts align; hedge with 25–35% stop or buy protective puts if price trades above implied volatility spikes.
• Relative value pair (short BMRN / long ASND): 6–12 month pair to express risk of market share shift in achondroplasia. Size net exposure small (1–2% portfolio) with stop if spread narrows >30%. Reward: capture 20–40% spread compression if Ascendis adoption accelerates; risk: Amicus assets or successful readouts reverse move.
• Conservative income (BMRN): Sell 6–9 month out‑of‑the‑money cash‑secured puts at a strike ~15% below current spot to collect premium if comfortable owning on headline dips. Risk: assignment and 15% downside; reward: premium income ~5–8% annualized if volatility remains elevated.
• Risk reduction (options hedge): If long equity exposure, buy short‑dated OTM puts around key readout dates (30–60 day) to cap peak drawdowns. Cost: ~1–3% notional per catalyst; benefit: limits downside from binary failures while preserving upside from integration success.